^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

DRD1 antagonist

7d
Repurposing of the Antipsychotic Trifluoperazine Induces SLC7A11/GPX4- Mediated Ferroptosis of Oral Cancer via the ROS/Autophagy Pathway. (PubMed, Int J Biol Sci)
The elevated expression level of GPX4 in oral cancer biopsies was also found to correlate with a poor prognosis. Together, these results provide evidence that TFP selectively induces GPX4-mediated, autophagy-dependent ferroptosis, thereby exerting anti-cancer effects against oral cancer and preventable death.
Journal
|
GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
14d
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine (clinicaltrials.gov)
P=N/A, N=40, Active, not recruiting, Seattle Institute for Biomedical and Clinical Research | N=20 --> 40
Enrollment change
|
olanzapine
27d
ITI-1284-301: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder (clinicaltrials.gov)
P2, N=705, Recruiting, Intra-Cellular Therapies, Inc. | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
Trial completion date • Trial primary completion date
27d
New P2 trial
28d
Deprescribing Antipsychotics in Long-Term Care (clinicaltrials.gov)
P=N/A, N=6, Completed, McMaster University | Unknown status --> Completed | N=20 --> 6
Trial completion • Enrollment change
|
olanzapine
1m
OBSERVSPEECH: Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses (clinicaltrials.gov)
P=N/A, N=200, Recruiting, Centre Hospitalier St Anne | Not yet recruiting --> Recruiting
Enrollment open • Adherence
|
olanzapine
1m
Regulation of ADAM10 activity through microdomain-dependent intracellular calcium changes. (PubMed, Cell Commun Signal)
The calmodulin-inhibitors trifluoperazine and ophiobolin A mediated delayed activation of ADAM10, which apparently did not depend on intracellular Ca2+ in the case of trifluoperazine...Finally, ADAM10 activation was observed after the entry of Ca2+ through certain channels, such as canonical members of transient receptor potential (TRP) channels. Therefore, the opening of particular channels for Ca2+ entry points and subsequent Ca2+ flux as well as the temporal aspects of the consequent increase in Ca2+ levels, must be considered for future therapeutic options involving the increasing or decreasing ADAM10 activity.
Journal
|
ADAM10 (ADAM Metallopeptidase Domain 10)
2ms
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder (clinicaltrials.gov)
P1, N=95, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
olanzapine
2ms
Aripiprazole, but Not Olanzapine, Alters the Response to Oxidative Stress in Fao Cells by Reducing the Activation of Mitogen-Activated Protein Kinases (MAPKs) and Promoting Cell Survival. (PubMed, Int J Mol Sci)
ARI de-sensitizes Fao cells to stress signaling, while OLA has the opposite effect. These findings contribute to our understanding of the metabolic risks associated with prolonged AAP use and may inform future therapeutic strategies.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
olanzapine
2ms
Effects of 6-week olanzapine treatment on serum IL-2, IL-4, IL-8, IL-10, and TNF-α levels in drug-naive individuals with first-episode schizophrenia. (PubMed, BMC Psychiatry)
Our results indicate that serum IL-2, IL-8, IL-10, and TNF-α levels may be involved in the pathophysiological mechanisms of schizophrenia and correlate with the effects of olanzapine.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4)
|
IL10 elevation
|
olanzapine
2ms
Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres. (PubMed, Neuro Oncol)
The synergistic combination of PER and TMZ has potential as a novel combination treatment strategy for GBM.
Journal
|
DRD2 (Dopamine Receptor D2)
|
temozolomide
3ms
Olanzapine Anorexia Cachexia (clinicaltrials.gov)
P3, N=164, Completed, Cairo University | Recruiting --> Completed
Trial completion
|
olanzapine
3ms
In silico study of some plant compounds as potential anticancer agents targeting MALT1 allosteric domain. (PubMed, J Biomol Struct Dyn)
Our findings from this computational study presents cyanidin (-8.822 kcal/mol) as better binder to the allosteric site of MALT1 based on the molecular docking and pharmacokinetic profiling than thioridazine...Hence, cyanidin is a potential allosteric inhibitor of MALT1. However, an urgent need for in vitro and in vivo validations is required to ascertain the efficacy of cyanidin in the fight against cancer and other MALT1-related diseases.
Journal
|
MALT1 (MALT1 Paracaspase)
3ms
New trial • Adherence
|
olanzapine
3ms
PSD-AOFC: Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression (clinicaltrials.gov)
P4, N=60, Completed, All India Institute of Medical Sciences, Bhubaneswar | Recruiting --> Completed
Trial completion
3ms
Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer (clinicaltrials.gov)
P2, N=170, Enrolling by invitation, Englewood Hospital and Medical Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
olanzapine
3ms
Fluspirilene exerts an anti-glioblastoma effect through suppression of the FOXM1-KIF20A axis. (PubMed, Neoplasma)
We investigated fluspirilene, perphenazine, and sulpiride, three classic anti-schizophrenic drugs, as possible anti-GBM agents. In fluspirilene-treated cells, FOXM1 protein was decreased, indicating that KIF20A was downregulated in the presence of the drug due to decreased FOXM1 protein. These results demonstrate that fluspirilene is an effective anti-GBM agent that works by suppressing the FOXM1-KIF20A oncogenic axis.
Journal
|
FOXM1 (Forkhead Box M1) • KIF20A (Kinesin Family Member 20A)
4ms
Trifluoperazine exerts anti-osteosarcoma effect by inducing mitochondria-dependent apoptosis via AKT/TXNIP signaling pathway. (PubMed, Toxicol Appl Pharmacol)
In vivo, TFP inhibited subcutaneous OS cell proliferation and induced OS cell apoptosis without noticeable side effects. In conclusion, our findings imply that TFP is a potential treatment for OS.
Journal
|
TXNIP (Thioredoxin Interacting Protein)
4ms
Trial completion
|
olanzapine
4ms
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC (clinicaltrials.gov)
P2, N=156, Not yet recruiting, Second Affiliated Hospital of Nanchang University
New P2 trial • IO biomarker • Metastases
|
Opdivo (nivolumab) • olanzapine
4ms
Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database. (PubMed, Biomed Pharmacother)
These findings suggest that fluphenazine has the potential to be used as an anti-breast cancer drug by inducing cuproptosis. Therefore, this research provides an insight for the development of novel cuproptosis-dependent anti-cancer agents.
Journal
|
FDX1 (Ferredoxin 1)
|
fluphenazine
4ms
Quetiapine Versus Trazadone in Women With Postpartum Depression (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Lawson Health Research Institute
New P1 trial
4ms
Characterization of SUSD3 as a novel prognostic biomarker and therapeutic target for breast cancer. (PubMed, Clin Transl Oncol)
The research emphasizes the significance of SUSD3 as a potential marker for BC, providing insights into the underlying molecular mechanisms implicated in tumorigenesis. SUSD3 holds promise in helping the classification of breast cancer pathological groups, predicting prognosis, and facilitating targeted therapy.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
fulvestrant • fluphenazine • raloxifene hydrochloride
5ms
Enrollment open • Metastases
|
carboplatin • paclitaxel • olanzapine
5ms
Olanzapine Modulate Lipid Metabolism and Adipose Tissue Accumulation via Hepatic Muscarinic M3 Receptor-Mediated Alk-Related Signaling. (PubMed, Biomedicines)
However, cotreatment with Cevimeline significantly reversed the lipid metabolic disturbance and adipose tissue accumulation, as well as the upregulation of the hepatic Alk signaling caused by Olanzapine. This study demonstrates evidence that Olanzapine may cause metabolic disturbance by modulating hepatic Alk signaling via M3R, which provides novel insight for modulating the hepatic Alk signaling and potential interventions for targeting metabolic disorders.
Journal
|
ALK (Anaplastic lymphoma kinase) • CHRM3 (Cholinergic Receptor Muscarinic 3) • PTPRZ1 (Protein Tyrosine Phosphatase Receptor Type Z1)
|
olanzapine
5ms
Olanzapine suppresses mPFC activity-norepinephrine releasing to alleviate CLOCK-enhanced cancer stemness under chronic stress. (PubMed, Cell Commun Signal)
We identify a new mechanism by which OLZ ameliorates chronic stress-enhanced tumorigenesis and chemoresistance. OLZ suppresses mPFC-NE-CLOCK axis to reverse chronic stress-induced anxiety-like behaviors and lung cancer stemness. Decreased NE-releasing prevents activation of ADRB2-cAMP-PKA-CREB pathway to inhibit CLOCK transcription, thus reversing lung cancer stem-like traits and chemoresistance under chronic stress.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • ADRB2 (Adrenoceptor Beta 2) • CLOCK (Clock Circadian Regulator)
|
gemcitabine • olanzapine
5ms
Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT (clinicaltrials.gov)
P1/2, N=30, Active, not recruiting, University of Pennsylvania | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date
5ms
New P3 trial
|
olanzapine
5ms
Synthesis and Structure of Novel Phenothiazine Derivatives, and Compound Prioritization via In Silico Target Search and Screening for Cytotoxic and Cholinesterase Modulatory Activities in Liver Cancer Cells and In Vivo in Zebrafish. (PubMed, ACS Omega)
Cytotoxicities of 28 PTZ derivatives (1-28) screened against Hep3B and SkHep1 liver cancer cell lines revealed five intermediate and five novel leads along with trifluoperazine (TFP), prochlorperazine (PCP), and perphenazine, which are relatively more cytotoxic than the basic PTZ core. Moreover, they modulated the cholinesterase activity or expression of ACHE in a cancer cell line-specific manner, and compound 10 significantly inhibited the cholinesterase activity in zebrafish. Accordingly, using a successful combination of in silico, in vitro, and in vivo approaches, we identified several lead anticancer and cholinesterase modulatory PTZ derivatives for future research.
Preclinical • Journal
|
ACHE (Acetylcholinesterase (Cartwright Blood Group))
5ms
Lung Adenocarcinoma Systems Biomarker and Drug Candidates Identified by Machine Learning, Gene Expression Data, and Integrative Bioinformatics Pipeline. (PubMed, OMICS)
Our drug repurposing analysis and molecular docking simulations suggested eight drug candidates for LUAD such as heat shock protein 90 inhibitors, cardiac glycosides, an antipsychotic agent (trifluoperazine), and a calcium ionophore (ionomycin). In summary, this study identifies several promising leads on systems biomarkers and drug candidates for LUAD. The findings also attest to the importance of integrative bioinformatics, structural biology and machine learning techniques in biomarker discovery, and precision oncology research and development.
Journal • Machine learning
|
BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1)
6ms
New P2 trial
6ms
TLK1 Inhibition Enhances the Anticancer Effect of Deep UV Irradiation Through CHK1 Activation. (PubMed, Anticancer Res)
TLK1 phosphorylation is an important event in DUV irradiation. DUV irradiation combined with TLK1 inhibition has therapeutic potential in pancreatic cancer cells.
Journal
|
CHEK1 (Checkpoint kinase 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • TLK1 (Tousled Like Kinase 1)
6ms
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients (clinicaltrials.gov)
P3, N=62, Terminated, University of Michigan Rogel Cancer Center | Active, not recruiting --> Terminated; Lack of Patient Population
Trial termination
|
carboplatin • paclitaxel • dexamethasone • fosaprepitant • olanzapine • ondansetron
7ms
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (clinicaltrials.gov)
P3, N=360, Recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Apr 2024 --> May 2026
Trial completion date • Trial primary completion date
|
megestrol • olanzapine
8ms
RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ) (clinicaltrials.gov)
P4, N=30, Not yet recruiting, University of Southern California | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jul 2024 --> Jul 2026
Trial completion date • Trial primary completion date
8ms
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer (clinicaltrials.gov)
P3, N=0, Withdrawn, Mayo Clinic | Trial completion date: Jun 2024 --> Dec 2024
Trial completion date • Metastases
|
olanzapine
8ms
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (clinicaltrials.gov)
P1, N=12, Recruiting, Intra-Cellular Therapies, Inc. | Not yet recruiting --> Recruiting
Enrollment open
8ms
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced and Incurable Solid Tumors (clinicaltrials.gov)
P2, N=66, Recruiting, OHSU Knight Cancer Institute | Suspended --> Recruiting | N=44 --> 66 | Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Jun 2025
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
olanzapine